BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27153559)

  • 1. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
    Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
    Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
    Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
    Dunne PD; McArt DG; O'Reilly PG; Coleman HG; Allen WL; Loughrey M; Van Schaeybroeck S; McDade S; Salto-Tellez M; Longley DB; Lawler M; Johnston PG
    Cancer Immunol Res; 2016 Jul; 4(7):582-91. PubMed ID: 27197062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
    Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
    Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
    Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
    Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer.
    Song K; Cai H; Zheng H; Yang J; Jin L; Xiao H; Zhang J; Zhao Z; Li X; Zhao W; Li X
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33855351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer.
    Nunez SK; Young CD; Griffen TL; Ohandjo AQ; McKinney LP; Kopetz S; Lillard JW
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
    Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability.
    Tanaka A; Wang JY; Shia J; Zhou Y; Ogawa M; Hendrickson RC; Klimstra DS; Roehrl MH
    Sci Rep; 2020 Dec; 10(1):22085. PubMed ID: 33328538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.